I discuss the impact that the U.S. Drug Enforcement Administration’s potential reclassification of cannabis would affect Georgia’s medical cannabis industry in his article published by Cannabis Industry Journal.
In particular, I consider three key areas of impact:
(1) How Georgia medical cannabis distributors would operate within this new regulatory framework;
(2) How this change would affect registered Georgia patients who are either currently purchasing medical cannabis or are planning to do so; and
(3) Whether this reclassification would cause big pharmaceutical companies to enter Georgia’s medical cannabis market, and if so, how.